日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

登録内容を編集
  このアイテムは取り下げられました。リリース履歴を表示詳細要約

取り下げ

学術論文

Drug repurposing for aging research using model organisms

MPS-Authors

Ziehm,  M.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Kaur,  S.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Ivanov,  D. K.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Ballester,  P. J.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Marcus,  D.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Partridge,  L.
Max Planck Institute for Biology of Ageing, Max Planck Society;

Thornton,  J. M.
Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource

(アクセスなし)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
フルテキスト (公開)
公開されているフルテキストはありません
付随資料 (公開)
There is no public supplementary material available
引用

Ziehm, M., Kaur, S., Ivanov, D. K., Ballester, P. J., Marcus, D., Partridge, L., & Thornton, J. M. (2017). Drug repurposing for aging research using model organisms. Aging Cell. doi:10.1111/acel.12626.


要旨
Many increasingly prevalent diseases share a common risk factor: age. However, little is known about pharmaceutical interventions against aging, despite many genes and pathways shown to be important in the aging process and numerous studies demonstrating that genetic interventions can lead to a healthier aging phenotype. An important challenge is to assess the potential to repurpose existing drugs for initial testing on model organisms, where such experiments are possible. To this end, we present a new approach to rank drug-like compounds with known mammalian targets according to their likelihood to modulate aging in the invertebrates Caenorhabditis elegans and Drosophila. Our approach combines information on genetic effects on aging, orthology relationships and sequence conservation, 3D protein structures, drug binding and bioavailability. Overall, we rank 743 different drug-like compounds for their likelihood to modulate aging. We provide various lines of evidence for the successful enrichment of our ranking for compounds modulating aging, despite sparse public data suitable for validation. The top ranked compounds are thus prime candidates for in vivo testing of their effects on lifespan in C. elegans or Drosophila. As such, these compounds are promising as research tools and ultimately a step towards identifying drugs for a healthier human aging.